# About Clinic TB-500 — Independent editorial publisher on TB-500 research

> Clinic TB-500 is an independent editorial project summarising peer-reviewed research on TB-500 and Thymosin Beta-4. Not a clinic. Not a vendor. Not medical advice.

Independent editorial commentary on the TB-500 and Thymosin Beta-4 peer-reviewed literature. The "clinic" in the name is framing — not a description of services.

## What this project is

Clinic TB-500 is an independent editorial project that publishes summaries of the peer-reviewed research literature on TB-500 (the synthetic seven-amino-acid Ac-LKKTETQ-OH heptapeptide) and its 43-amino-acid parent peptide Thymosin Beta-4. The site is editorial commentary on publicly available science. The dark-mode console aesthetic is meant to read as a research-platform reading interface — a cinematic operator console for inspecting the TB-500 / Tβ4 record.

We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. We do not refer readers to a vendor. The "clinic" in the domain name is editorial framing — a position the publisher occupies relative to the literature, not a claim about the site's services.

## What we do not do

We do not recommend doses. The dosage page surveys what doses have appeared in published research studies and registered clinical trials, by species and route, and explicitly refuses to translate those numbers into human-use guidance. We do not employ doctors, pharmacists, nurses, or any clinical staff. We do not maintain a physical location. We do not maintain a phone line or appointment system.

We do not sell TB-500 or Thymosin Beta-4. We do not affiliate with any compounding pharmacy, research-chemical vendor, or biotech sponsor. We are not affiliated with RegeneRx, HLB Therapeutics, ReGenTree, or any other party named in the published clinical record. We are independent.

## How we source

Every quantitative claim on this site attaches to a peer-reviewed citation in the references console. Twenty-six sources at the time of writing. The mix is roughly two-thirds preclinical (rodent, porcine, equine, in-vitro biochemistry, X-ray crystallography), one-quarter human clinical (Phase I safety in healthy volunteers, Phase II/III RGN-259 ophthalmic and RGN-352 IV cardiac programmes, the clinical-biomarker record), and the remainder review and regulatory.

We prefer primary sources — PubMed-indexed peer-reviewed journals, ClinicalTrials.gov registry pages, FDA dockets, published trial readouts. We cite review articles where they provide consolidated context, and we are explicit about which claims rest on rodent data versus human data versus vendor extrapolation. Where the published evidence is sparse (the seven-amino-acid TB-500 heptapeptide has no registered human PK or efficacy trial), we say so directly.

## Editorial standards

No medical advice. No recommendations for human use. No personal anecdotes. No comparative claims that imply equivalence between the seven-amino-acid TB-500 fragment and full-length 43-amino-acid Thymosin Beta-4 — the disambiguation is treated as the first editorial duty of the site. No competitor brand names. No outbound links to vendors or research-chemical suppliers. Outbound links lead only to primary peer-reviewed sources, ClinicalTrials.gov registry pages, FDA dockets, and major regulator publications.

This is an editorial research digest — independent commentary on publicly available science. It is not a clinical service and does not employ clinicians.

---

An independent editorial console for the peer-reviewed record — not a clinic, not a vendor, not medical advice.